-
Major Win: First Batch of Dolutegravir Arrives in Colombia Under a Compulsory License
The World Health Organization (WHO) recommends dolutegravir as the first- and second-line treatment for all population groups. In Colombia, access...
-
Activists at AIDS2024 called on ViiV Healthcare to drop their case in Colombia against Compulsory License on Dolutegravir
On the 24th of July, hundreds of treatment advocates attending AIDS2024 in Munich protested against the companies with “Drop The...
-
Brazilian Community-Based Organization ABIA Bids to Expand HIV Treatment Access by Overriding the Patent on Dolutegravir
The Brazilian Interdisciplinary AIDS Association (ABIA), an advocacy group in Rio de Janeiro, has called on the Ministry of Health...
-
Dolutegravir – DTG
Dolutegravir was approved by the United States Food and Drug Administration in 2013. Dolutegravir is also known as DTG.
-
Civil Society Organizations in Brazil fight for better access to Dolutegravir
Brazilian Interdisciplinary AIDS Association (ABIA), along with the Working Group on Intellectual Property (GTPI) of the Brazilian Network for the...
-
Belarus: Civil society pushes for compulsory license as dolutegravir remains overpriced
Positive Movement (PMPlus) in Belarus, one of our partner organizations, is an NGO representing people living with HIV, advocating for...
-
Letter to ViiV Healthcare: No more time to waste – increase access to dolutegravir in Eastern Europe and Central Asia
Dolutegravir is an essential drug in HIV treatment, recommended by the World Health Organization (WHO). Despite the drug being approved...
-
ITPC backs fight against replacement of HIV drug dolutegravir in El Salvador
For more than a month, people living with HIV in El Salvador’s capital city have been surviving a shortage of...
-
The right to health is compulsory: Time for action on dolutegravir – now!
Why Algeria, Azerbaijan, Belarus, Brazil, Bulgaria, China, Colombia, Kazakhstan, Mexico, Romania, Russia, and Turkey must issue compulsory licences on dolutegravir...
-
FAQs for women of childbearing potential and dolutegravir: Key interim considerations
A forum on the risks of preconception dolutegravir exposure has pulled together frequently asked questions (FAQs) designed to help provide...
-
“We want dolutegravir for all, and we want it now.”
Article first published on the Huffington Post here. We’re calling for a compulsory license on a ‘new’ HIV drug to...
-
The Roadmap – Special Edition Report on Dolutegravir
The Initiative for Medicines, Access and Knowledge (I-MAK), has published a special edition ‘Roadmap report’ on dolutegravir. The report provides...
